scholarly journals Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment

2021 ◽  
Vol 12 ◽  
Author(s):  
Mengli Guo ◽  
Zhen Chen ◽  
Yayi Li ◽  
Sijin Li ◽  
Fei Shen ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Predictor Variable ◽  
Gene Set Enrichment Analysis ◽  
Recurrence Free Survival ◽  
Papillary Thyroid ◽  
Immune Microenvironment ◽  
Free Survival ◽  
Tumor Mutation Burden ◽  
Mutation Burden

BackgroundThe risk factors of papillary thyroid carcinoma (PTC) recurrence are meaningful for patients and clinicians. Tumor mutation burden (TMB) has been a biomarker for the effectiveness of immune checkpoint inhibitor (ICI) and prognosis in cancer. However, the role of TMB and its latent significance with immune cell infiltration in PTC are still unclear. Herein, we aimed to explore the effect of TMB on PTC prognosis.Material and MethodsRNA-seq and DNA-seq datasets of PTC patients were downloaded from The Cancer Genome Atlas (TCGA) database. The Gene Ontology (GO) and gene set enrichment analysis (GSEA 4.0.1) were applied further to explore potential differences in PTC patients’ biological functions. The differentially expressed genes (DEGs) and immune microenvironment between the high and low TMB groups were determined.ResultsTMB had the highest AUC score than other clinical indicators in ROC analysis on recurrence-free survival, and a higher TMB score was related to a worse prognosis. Further, GSEA showed a higher level of oxidative phosphorylation (OXPHOS) in the high TMB group, and four genes correlated with recurrence-free survival rate were identified. The abundance of CD8+ T cells and M1 macrophages in the high TMB group was significantly lower than that in the low TMB group.ConclusionsOur study found that TMB was a better predictor variable at evaluating the risk of PTC recurrence. Moreover, TMB-related genes conferred dramatically correlated prognosis, which was worth exploring in guiding postoperative follow-up and predicting recurrence for PTC patients.

scholarly journals CD73 Overexpression Promotes Progression and Recurrence of Papillary Thyroid Carcinoma

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 3042 ◽  
Author(s):  
Young Mun Jeong ◽  
Haejin Cho ◽  
Tae-Min Kim ◽  
Yourha Kim ◽  
Sora Jeon ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
High Expression ◽  
Migration And Invasion ◽  
Recurrence Free Survival ◽  
Papillary Thyroid ◽  
Tumor Immune Escape ◽  
Free Survival ◽  
Mesenchymal Transition ◽  
Cd73 Expression

CD73 is involved in tumor immune escape and promotes the growth and progression of cancer cells. The functional role of CD73 expression in papillary thyroid carcinoma (PTC) has not yet been established. In 511 patients with PTC, immunohistochemistry for CD73 on tissue microarrays showed that the high expression of CD73 was associated with an aggressive histologic variant (p = 0.002), extrathyroidal extension (p < 0.001), lymph node metastasis (p < 0.001), and BRAFV600E mutation (p = 0.015). Survival analysis results showed that patients with high CD73 expression had worse recurrence-free survival (p = 0.023). CD73 inhibitors induced G1 cell cycle arrest and apoptosis, inhibited the migration and invasion of PTC cells, and suppressed tumor growth in PTC xenograft nude mice. High expression of CD73 (NT5E) mRNA was associated with unfavorable clinicopathologic characteristics, the abundance of Tregs and dendritic cells, depletion of natural killer (NK) cells, and high expression of immune checkpoint genes and epithelial-to-mesenchymal transition-related genes in The Cancer Genome Atlas (TCGA) dataset. Taken together, CD73 expression promotes tumor progression and predicts low recurrence-free survival. Targeting the CD73–adenosine axis in the tumor microenvironment offers an attractive pathway for therapeutic strategies aimed at advanced PTC.

Abstract LBA042: Male Sex is an Independent Predictor of Recurrence-Free Survival in Middle Eastern Papillary Thyroid Carcinoma

2021 ◽  
Author(s):  
KHAWLA S. AL-KURAYA ◽  
Sandeep Kumar Parvathareddy ◽  
Abdul K Siraj ◽  
Felisa De Vera ◽  
Padmanaban Annaiyappanaidu ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Independent Predictor ◽  
Middle Eastern ◽  
Recurrence Free Survival ◽  
Papillary Thyroid ◽  
Free Survival ◽  
Male Sex

Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis

2020 ◽  
Vol 89 ◽  
pp. 107090
Author(s):  
Zhenyu Xie ◽  
Xin Li ◽  
Yu Lun ◽  
Yuzhen He ◽  
Song Wu ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Poor Prognosis ◽  
Papillary Thyroid ◽  
Tumor Mutation Burden ◽  
Mutation Burden

scholarly journals Correlates of Recurrence-Free Survival in Papillary Thyroid Carcinoma: A Cohort Study in an Iranian Population

2021 ◽  
Vol 25 (4) ◽  
pp. 351-360
Author(s):  
Bahareh SHATERI AMIRI ◽  
Mahboobeh HEMMATABADI ◽  
Soghra RABIZADEH ◽  
Hamideh HASANNEJAD ◽  
Alireza ESTEGHAMATI ◽  
...  
Keyword(s):  
Cohort Study ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Iranian Population ◽  
Recurrence Free Survival ◽  
Papillary Thyroid ◽  
Free Survival

Extensive surgery improves recurrence-free survival for children and young patients with class I papillary thyroid carcinoma

1999 ◽  
Vol 34 (12) ◽  
pp. 1799-1804 ◽  
Author(s):  
Catherine A Welch Dinauer ◽  
R.Michael Tuttle ◽  
Daniel K Robie ◽  
Donald R McClellan ◽  
Gary L Francis
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Young Patients ◽  
Class I ◽  
Recurrence Free Survival ◽  
Papillary Thyroid ◽  
Free Survival ◽  
Extensive Surgery

scholarly journals Prognostic value of lymph node ratio in metastatic papillary thyroid carcinoma

2017 ◽  
Vol 132 (1) ◽  
pp. 8-13 ◽  
Author(s):  
J Mansour ◽  
D Sagiv ◽  
E Alon ◽  
Y Talmi
Keyword(s):  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Prognostic Value ◽  
Lymph Node Ratio ◽  
Regional Recurrence ◽  
Recurrence Free Survival ◽  
Papillary Thyroid ◽  
Free Survival ◽  
Node Ratio

AbstractObjective:Cervical metastases in papillary thyroid carcinoma are associated with increased recurrence. However, their effect on survival remains controversial. This study evaluated literature on the prognostic value of lymph node ratio for loco-regional recurrence and survival in metastatic papillary thyroid carcinoma.Methods:The PubMed database was systematically searched using the terms ‘papillary thyroid carcinoma’ and ‘lymph node ratio’. Articles addressing the association between lymph node ratio and loco-regional recurrence or survival were identified.Results:Nine retrospective studies were included, comprising 12 400 post-thyroidectomy and neck dissection papillary thyroid carcinoma patients (median age, 48.6 years; 76 per cent females). Lymph node ratio was associated with worse recurrence-free survival in 60 and 75 per cent of studies investigating the effect of central compartment metastases and both central and lateral compartment metastases on recurrence-free survival, respectively. One large population-based study showed an association between lymph node ratio and disease-specific mortality in N1nodal disease, but failed to maintain the same association when N1bpatients were excluded.Conclusion:Regional lymph node ratio is an independent predictor for loco-regional recurrence in pathologically staged N1patients with papillary thyroid carcinoma. Patients with a high lymph node ratio should be closely followed up.

scholarly journals Should Contralateral Nodules Be an Indication of Total or Completion Thyroidectomy for Patients With Unilateral Papillary Thyroid Carcinoma?

2021 ◽  
Vol 12 ◽  
Author(s):  
Tengfei Ma ◽  
Haiyang Wang ◽  
Jifeng Liu ◽  
Jian Zou ◽  
Shixi Liu
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Survival Rates ◽  
Recurrence Free Survival ◽  
Completion Thyroidectomy ◽  
Papillary Thyroid ◽  
Free Survival ◽  
Benign Nodules ◽  
Disease Specific

ObjectiveTo determine whether papillary thyroid carcinoma (PTC) patients with benign or nonsuspicious nodules in the contralateral lobe have a higher rate of recurrence or worse survival after lobectomy compared to those without nodules in the contralateral lobe.MethodsAdult patients who underwent lobectomy and were diagnosed with unilateral PTC (2013-2015), were identified from an institutional database. Patients who previously had cytologically benign nodules or nonsuspicious nodules in the contralateral lobe comprised the contralateral nodule (CN) group. Patients who did not have nodules in the contralateral lobe comprised the unilateral nodule (UN) group.Results370 patients were included: 242 in the UN group and 128 in the CN group. After a median follow-up of 62 months (range, 16–85 months), recurrence was confirmed in 4.1% patients in the UN group and 5.5% patients in the CN group (p = 0.559). Clinical contralateral lobe PTC was detected in 2.9% (7/242) of patients from the UN group and 3.9% (5/128) of patients from the CN group (p = 0.601). The 5-year contralateral lobe recurrence-free survival (RFS) rates were 96.8% in the UN group and 97.4% in the CN group (p = 0.396). The 5-year loco-regional RFS rates were 98.4% in the UN group and 97.8% in the CN group (p = 0.690). The 5-year disease-specific survival rates were both 100%.ConclusionPTC patients with benign or nonsuspicious CNs have similar recurrence and survival rates after lobectomy compared to those without CNs. CNs alone should not be an indication for total or completion thyroidectomy.

Sign in / Sign up

Export Citation Format

Share Document